« Previous
Next »
American Journal of Kidney Diseases
Volume 51, Issue 4,
Supplement 2
, Pages
S13-S20
, April 2008
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004
-
Participants detected with chronic kidney disease by stage in Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Chronic kidney disease stages were d
Participants detected with chronic kidney disease by stage in Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Chronic kidney disease stages were defined as follows: stage 1, estimated glomerular filtration rate (eGFR) greater than 90 mL/min/1.73 m2 and albumin-creatinine ratio (ACR) of 30 mg/g or greater; stage 2, eGFR of 60 to 89 mL/min/1.73 m2 and ACR of 30 mg/g or greater; stage 3, eGFR of 30 to 59 mL/min/1.73 m2; stage 4, eGFR of 15 to 29 mL/min/1.73 m2; and stage 5, eGFR less than 15 mL/min/1.73 m2. To convert eGFR from mL/min/1.73 m2 to mL/s/1.73 m2, multiply by 0.01667.
-
Chronic kidney disease risk factors in the Kidney Early Evaluation Program. Percentages of self-reported characteristic risk factors grouped by stage. Chronic kidney disease stages were defined as folChronic kidney disease risk factors in the Kidney Early Evaluation Program. Percentages of self-reported characteristic risk factors grouped by stage. Chronic kidney disease stages were defined as follows: stage 1, estimated glomerular filtration rate (eGFR) greater than 90 mL/min/1.73 m2 and albumin-creatinine ratio (ACR) of 30 mg/g or greater; stage 2, eGFR of 60 to 89 mL/min/1.73 m2 and ACR of 30 mg/g or greater; stage 3, eGFR of 30 to 59 mL/min/1.73 m2; stage 4, eGFR of 15 to 29 mL/min/1.73 m2; and stage 5, eGFR less than 15 mL/min/1.73 m2. To convert eGFR from mL/min/1.73 m2 to mL/s/1.73 m2, multiply by 0.01667. Abbreviations: DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease.
A list of the members of the Kidney Early Evaluation Program Investigators appears at the end of this article.
PII: S0272-6386(08)00004-8
doi: 10.1053/j.ajkd.2007.12.016
© 2008 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved.
« Previous
Next »
American Journal of Kidney Diseases
Volume 51, Issue 4,
Supplement 2
, Pages
S13-S20
, April 2008
